Quick Facts

• Primary Indication: Management of symptoms associated with feeling sick and being sick.
• Key Therapeutic Benefit: Relief of symptoms of nausea and vomiting.
• Duration of Use: Generally limited to short-term therapy, typically not exceeding one week.

---

Dompy (domperidone) is a medication authorized for the relief of symptoms of nausea and vomiting in adults and adolescents aged 12 years and older, with a body mass of 35 kg or more. Its principal therapeutic effect is to help alleviate the sensations of feeling sick and to reduce episodes of being sick. By facilitating movement in the upper gastrointestinal system, it provides symptomatic relief.

This medicine is primarily recommended for short-term use, generally restricted to a maximum treatment duration of one week, as determined by a healthcare professional.

Eligibility Map: Who Can and Cannot Use Domperidone

The eligibility profile for Domperidone (Dompy) is strictly defined by regulatory documents, primarily based on avoiding cardiac and gastrointestinal risks.

Populations for Whom Use is Contraindicated

Domperidone is contraindicated in several groups due to increased safety risks, including:

• Patients with pre-existing cardiac conditions, specifically those with prolongation of the QTc interval, significant electrolyte disturbances (like hypokalemia), or congestive heart failure.
• Patients with moderate or severe hepatic impairment.
• Patients with a prolactin-releasing pituitary tumour (prolactinoma).
• Patients in whom stimulating gastrointestinal motility would be dangerous, such as those with gastrointestinal hemorrhage, mechanical obstruction, or perforation.
• Children under 12 years of age and adolescents weighing less than 35 kg due to a lack of established efficacy and safety concerns.

Age- and Condition-Specific Restrictions

Older adults (over 60 years) and patients with severe renal impairment require special consideration. Use in these groups is permitted but restricted to the lowest effective dose for the shortest possible duration. Domperidone is generally not recommended for use during pregnancy or breastfeeding.

The official interaction profile for Domperidone (Dompy) is structured around two non-negotiable prohibitions aimed at minimizing cardiac risk. Co-administration with potent CYP3A4 inhibitors, such as Ketoconazole, Erythromycin, Clarithromycin, and Itraconazole, is formally contraindicated. This pharmacokinetic restriction is due to regulatory evidence that these medicines significantly increase Domperidone’s systemic exposure by reducing its clearance. Co-administration with other medicinal products known to prolong the QTc interval is also formally contraindicated due to a pharmacodynamic additive effect that increases the risk of serious ventricular arrhythmias.

---

The interaction profile also outlines mandatory restrictions involving timing and non-medicinal substances. Antacids and antisecretory agents are documented to lower the oral bioavailability of Domperidone; therefore, a timing separation is required, with Domperidone taken before meals and these other agents taken after. The concurrent consumption of Grapefruit Juice must be avoided as it acts as a CYP3A4 inhibitor. Additionally, Domperidone is contraindicated for use in patients with moderate or severe hepatic impairment due to pre-existing clearance issues that lead to a high risk of increased systemic exposure and related interaction potential.

How Dompy Works

Dompy functions as a dopamine D2 receptor antagonist, primarily exerting its effects on systems outside the main brain barrier. The drug's mechanism is defined by its action on three distinct areas.

First, in the peripheral nervous system of the gastrointestinal tract, its binding blocks D2 receptors on smooth muscles and nerve endings. This action removes the natural inhibitory effect of dopamine, leading to stronger, more coordinated muscle contractions (peristalsis) in the stomach and upper small intestine.

Second, the antagonist activity in the chemoreceptor trigger zone (CTZ) near the brainstem prevents the transmission of signals that initiate the emetic reflex. This systemic modulation results in an increase in the signal intensity required to trigger the physical reflex.

Finally, by blocking D2 receptors in the anterior pituitary gland, the drug removes the dopamine-mediated inhibition of prolactin release, leading to an increase in prolactin secretion.

How Dompy is Used: Official Administration Guidelines

Dompy (domperidone) is used according to specific, standardized instructions. These guidelines define the dosage, administration route, timing, and duration of use.

---

Administration Details

Feature	Official Instruction
Route of Administration	Primarily Oral (tablets, suspension, drops); also available Rectally (suppositories).
Timing in Relation to Meals	Oral forms must be taken before meals (preprandially) for proper absorption.
Preparation	Tablets must be swallowed whole. Oral drops or suspension require a calibrated dosing device for accurate measurement.
Missed Dose	If a dose is missed, it should be omitted, and the standard schedule resumed; do not take a double dose.

---

Official Dosing and Duration

For adults and adolescents weighing 35 kg or more, the dosing regimen is strictly controlled:

• Standard Oral Dose: 10 mg per dose.
• Dosing Frequency: Up to three times a day, taken at regular intervals.
• Maximum Daily Dose: The total dose must not exceed 30 mg in a 24-hour period.
• Treatment Duration: Domperidone is restricted to short-term use, for a maximum of seven consecutive days. Treatment should be discontinued immediately upon symptom resolution.

---

Population-Specific Use

Official guidelines detail adjustments for specific patient groups, such as those with impaired organ function. Patients with severe renal impairment must have their dosing frequency reduced to once or twice daily, depending on the severity, as determined by a healthcare professional. Conversely, Domperidone is generally not used in patients with moderate to severe hepatic impairment.

Research evidence / Overview of studies for Dompy

Evidence for Use in Symptomatic Relief of Nausea and Vomiting

Research involving domperidone includes short-term Randomized Controlled Trials (RCTs). These studies were structured to compare the medicine against a control to explore how symptoms change over time. Researchers focused on outcomes related to physical discomfort and episodic changes, specifically measuring patient-reported symptom scores for the severity of nausea and the documented frequency of vomiting over brief periods. These studies observed responses over defined time intervals, relevant in trials assessing short-term or episodic symptom patterns.

The systematic reviews and regulatory evaluations of these trials described the study of the medicine for these acute symptoms in adults and adolescents (aged 12 years and older). Findings describe patterns observed in the studies where reported measurements of nausea severity and vomiting frequency were tracked during the trial period. This research provides insight into short-term changes and contributes to the understanding of this specific area of research.

---

Research Exploring Gastrointestinal Motility Disorders

Domperidone was evaluated in a different set of research for specific conditions marked by functional limitations, such as gastroparesis. Because these are chronic conditions where symptoms may vary in intensity, research examined how domperidone was observed in patients with chronic, refractory conditions. The study types in this area include observational cohort studies and specialized, long-term clinical protocols conducted in specialized centers.

In these contexts, researchers studied outcomes related to both physical discomfort and systemic or functional imbalance. Studies involved long-term observation using tools like the Gastroparesis Cardinal Symptom Index, and they also examined objective measurements of gastric emptying rates. Studies report how symptoms evolved in the observed populations, and the research documents the process of measuring gastric emptying in some patients.

---

Follow-up and Research into Duration of Effect

The research exploring short-term symptom changes, particularly for acute nausea and vomiting, generally involved follow-up durations that were limited, often to a maximum of one week. This focus means the evidence for the main approved use is primarily focused on outcomes measured related to episodic or acute changes during the treatment phase.

For the chronic conditions, studies explored responses over defined time intervals that were much longer. This research contributes to understanding symptom patterns over time in these specific, complex conditions; however, robust long-term data derived from large, controlled trials remains limited.

Key Studies & References

1. Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents (MHRA Drug Safety Update)
2. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis (CRD Summary)

Common questions about Dompy (FAQ)

Q: What is the official safety classification of Dompy?

Following regulatory reviews concerning the medicine's potential cardiac risk, Dompy's official safety status was restricted in many countries. Regulatory bodies reclassified it from an Over-the-Counter (OTC) drug to a prescription-only medicine (POM). This classification means the medicine requires a prescription and is supplied under the supervision of a healthcare professional.

---

Q: Are there different brand names for the medicine Dompy?

Yes. The active ingredient in this medicine is domperidone. This compound is manufactured and sold under many different brand names around the world, one of the most widely recognized being Motilium.

---

Q: Is there a generic version of Dompy available?

Yes, Dompy is the name for the active ingredient itself, domperidone, which is the generic name. The product is widely available as a generic medicine in various forms, as well as under different brand names.

---

Q: How quickly does Dompy start working after taking it?

According to pharmacokinetic data found in official product information, Dompy is rapidly absorbed after being taken orally. The concentration of the active ingredient in the blood typically reaches its peak within one hour to one and a half hours after dosing.

---

Q: How long does the effect of one dose of Dompy typically last?

The official administration guidelines provide insight into the duration of action. Since the medicine is typically prescribed to be taken up to three times per day, this dosing schedule is consistent with the goal of providing relief from acute symptoms for a duration of several hours per dose.

---

Q: What are the main differences between Dompy and similar medications?

Official documents describe Dompy (domperidone) as a dopamine receptor antagonist, a type of medicine that blocks certain chemical signals. A key characteristic of its action is that it works primarily outside the central nervous system (CNS) (the brain and spinal cord). This difference in its site of action distinguishes it from some other medicines in the antiemetic category.

---

Q: Is it safe to take Dompy with antacids?

Official instructions address taking Dompy with antacids and similar medications. Regulatory documents note that these other agents may reduce the absorption of Dompy, potentially making it less effective. For this reason, official guidance describes taking Dompy before meals and taking antacids or antisecretory agents (like those for reducing stomach acid) after meals.

---

Q: Does Dompy interact with common allergy medications?

Official warnings state that Dompy is contraindicated (must not be taken) with any medicine known to prolong the QTc interval. Official documents note that this combination may increase the risk of heart rhythm problems. Co-administration is formally contraindicated (must not be taken together).

---

Q: Do any herbal supplements interact with Dompy?

The official interaction profile strictly contraindicates use with potent CYP3A4 inhibitors, which are substances that interfere with how the body breaks down the medicine. Because many herbal supplements can potentially affect how the body metabolizes medicines, official documents advise caution regarding the use of supplements with any prescribed medication.

---

Q: Can Dompy cause stomach pain or upset?

Official safety labeling documents list several possible adverse reactions. Abdominal cramps and diarrhea are documented as uncommon side effects of Dompy. Official records indicate that these effects have been documented in patients.

Official Storage and Disposal Requirements for Dompy

Regulatory documents mandate specific conditions for storing Dompy (domperidone) to ensure stability and safety. This medicine should be stored at room temperature, typically between 15°C and 30°C. It is required to protect the product from light and moisture, and it must be kept in its original, tightly closed container or packaging.

Prohibited Storage Environments:

• Do not refrigerate.
• Do not freeze.

To prevent accidental ingestion, Dompy must be stored out of the sight and reach of children. For disposal, unused or expired medication should not be flushed down a toilet or placed in household trash. It must be disposed of in accordance with local regulations, often by taking it to a pharmacy take-back program or approved collection site, to prevent environmental contamination.